<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04379180</url>
  </required_header>
  <id_info>
    <org_study_id>2020_PPHN_001</org_study_id>
    <nct_id>NCT04379180</nct_id>
  </id_info>
  <brief_title>Population Pharmacokinetics and Dosage Individualization of Oral Pulmonary Vasodilators in PPHN</brief_title>
  <official_title>Population Pharmacokinetics and Dosage Individualization of Bosentan, Sildenafil and Tadalafil in Persistent Pulmonary Hypertension of the Newborn</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>West China Second University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of bosentan, sildenafil and tadalafil in neonates with persistent pulmonary
      hypertension (PPHN) depends mostly on the empirical experience of pediatricians. Moreover,
      the recommended dose of those three drugs in treating PPHN remains controversial. Therefore,
      our aim is to study the pharmacokinetics and pharmacodynamics of bosentan, sildenafil and
      tadalafil in neonates of PPHN then dose a tailor-made therapeutic regimen.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 26, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 26, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Oxygenation index</measure>
    <time_frame>The first 72 hours of the initial treatment</time_frame>
    <description>Oxygenation index=(fraction of inspired oxygen*mean airway pressure)/the partial pressure of arterial oxygen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of hemodynamics</measure>
    <time_frame>Through study completion, an average of 5 days</time_frame>
    <description>Pulmonary artery pressure (mmHg)
Alveolar-arterial gradient (mmHg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>Within the first 28 days of patients' life</time_frame>
    <description>Duration of initial therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Within the first 28 days of patients' life</time_frame>
    <description>Death in the first 28 days of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Through study completion, an average of 5 days</time_frame>
    <description>Drug-related adverse events and serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequelae of PPHN</measure>
    <time_frame>Through study completion and a 6-month visit</time_frame>
    <description>Including cerebral palsy, hearing impairment, neurodevelopmental outcome etc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The need of extra support</measure>
    <time_frame>Through study completion, an average of 5 days</time_frame>
    <description>Besides the initial therapy (bosentan, sildenafil and/or tadalafil), other support such as inhaled nitric oxide (iNO), inotropic agents or Extracorporeal Membrane Oxygenation (ECMO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse oxygen saturation</measure>
    <time_frame>The first 72 hours of the initial treatment</time_frame>
    <description>Pulse oxygen saturation（%）</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Persistent Pulmonary Hypertension of the Newborn</condition>
  <arm_group>
    <arm_group_label>Treatment(bosentan, sildenafil and tadalafil)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentan Tablets</intervention_name>
    <description>2mg/kg, bid</description>
    <arm_group_label>Treatment(bosentan, sildenafil and tadalafil)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil Tablet</intervention_name>
    <description>1mg/kg, q6h/q8h</description>
    <arm_group_label>Treatment(bosentan, sildenafil and tadalafil)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil Tablets</intervention_name>
    <description>1mg/kg, qd</description>
    <arm_group_label>Treatment(bosentan, sildenafil and tadalafil)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Neonates suffered from persistent pulmonary hypertension
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: postnatal age ≤ 28 days;

          -  Patients have been diagnosed with PPHN;

          -  Bosentan, sildenafil and/or tadalafil used as part of regular treatment.

          -  Parental written consent

        Exclusion Criteria:

          -  Expected survival time less than the treatment cycle;

          -  Major congenital malformations;

          -  Undergoing surgery within the first week of life;

          -  Receiving other systemic trial drug therapy;

          -  Other factors that the researcher considers unsuitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West China Second University Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wei Zhao, Ph.D</last_name>
      <phone>86053188383308</phone>
      <email>zhao4wei2@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 26, 2020</study_first_submitted>
  <study_first_submitted_qc>May 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Wei Zhao</investigator_full_name>
    <investigator_title>Head of department of clinical pharmacy and pharmacology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Persistent Fetal Circulation Syndrome</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

